***Registration for this event is now closed, in order to join our waitlist please email laurabacchus@onenucleus.com***

Context

Efficiently progressing innovative medicines from research into pre-clinical and first-in-man studies is important in maximising value creation in any biotech or Pharma company. That progress however must be based on robust studies to increase the probability of success. This BioWednesday event, led by tranScrip will discuss how investors and entrepreneurs evaluate small companies for investment. We will give you hints and tips to take away that will help inform your critical decisions. We will explore how companies managed to navigate the hurdles towards the clinic, what made the difference, pain points, and bugbears.

We hope that you can join us afterwards for networking and refreshments.

Programme: 

15.00 - Arrival, Registration and Networking
15.30 - Welcome from Tony Jones, CEO, One Nucleus
15.40 - Innovation Presentations
17.20 - Refreshments and Networking
17.40 - Panel Discussion 
Chair
Judit Molnar, tranScrip
Panel
Anne Phelan, Benevolent AI 
Bradley Hardiman, Astellas 
Leslie Dowling, tranScrip 
Chris Brearley, tranScrip
18.40 - Closing Remarks 
18.50 - Drinks Reception 
19.30 - Close

One Nucleus members: Free
Non-Members: £50 + VAT

Academics: please contact jasmin@onenucleus.com